We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.
Investigator, CHEO Research Institute